A synthetic peptide coming off a reverse-phase HPLC column is almost never a free base. It is a salt, and its counterion, most often trifluoroacetate (TFA), is a separate specification from purity that is easy to miss on a certificate of analysis (COA). Counterion mass is part of a vial's total weight but is not peptide, which changes net peptide content. Residual TFA has also been examined in the literature as a possible confound in some cell-based assays. And exchanging a peptide from its default TFA salt to acetate or hydrochloride is a distinct processing step, not a purity upgrade. This article covers what a counterion is, why TFA appears by default, what cell culture studies have reported about residual TFA, how salt exchange is performed, how the salt form is recorded on a COA, and the BPC-157 arginate and acetate forms as an example of salt-form variation.
| Attribute | Detail |
|---|---|
| Default salt form after synthesis | Trifluoroacetate (TFA), carried over from the TFA used during cleavage and as an ion-pairing agent in reverse-phase HPLC |
| Why TFA ends up bound to the peptide | TFA anions pair with protonated basic side chains and the free N-terminus, and remain associated through lyophilization |
| Effect on weight | Counterion mass is part of the lyophilized powder's total weight but is not peptide, lowering net peptide content |
| Cell culture consideration | Residual TFA has been reported to alter cytotoxicity and activity readouts in some cell-based assays, separate from the peptide's own effect |
| Common alternative salt forms | Acetate, hydrochloride, and occasionally other organic acid salts such as arginate |
| How exchange is performed | Ion-exchange chromatography or repeated lyophilization from a dilute acetic acid or hydrochloric acid solution |
| Where it appears on a COA | Listed as salt form or counterion, sometimes with a separate counterion-content percentage distinct from HPLC purity |
Why do peptides come off HPLC as TFA salts?
Solid-phase peptide synthesis uses TFA both to cleave the finished chain from resin and to remove protecting groups, and reverse-phase HPLC purification commonly uses dilute TFA, around 0.05 to 0.1 percent, in the mobile phase as an ion-pairing agent that sharpens peak shape for basic peptides. Because TFA is present throughout cleavage and purification, its anion pairs with protonated basic side chains, arginine, lysine, histidine, and the N-terminal amine, when the purified fractions are lyophilized. The result is a peptide-TFA salt by default, not a chosen counterion, simply the anion already present in the solvent system. For more on that purification step, see HPLC purity explained and solid-phase peptide synthesis explained.
What is a counterion, and why does every basic peptide need one?
A counterion is the oppositely charged ion that balances a peptide's net charge in the solid state. A peptide with protonated basic residues carries a positive charge at the pH used during purification, and an anion, TFA by default, pairs with it so the isolated solid is electrically neutral. This is separate from purity: HPLC purity describes chromatographic homogeneity of the peptide peak, while counterion identity and content describe what else is in the powder. A lot can report high HPLC purity and still carry a meaningful counterion load; see net peptide content vs purity for how the two are calculated.
How does a TFA counterion affect weight and net peptide content?
Trifluoroacetate has a molecular weight of about 114 daltons. For a short peptide with several basic residues, each bound TFA anion adds measurable mass, so a vial's total weight includes peptide, counterion, residual water, and any other salts present. Net peptide content strips out everything that is not the peptide chain, and counterion mass is one of the largest contributors to that gap for basic, multiply-charged sequences. A COA reporting only HPLC purity, with no net peptide content figure, leaves this gap unaccounted for.
What have cell culture studies reported about residual TFA?
Because TFA itself is not biologically inert, several studies have compared peptides carrying different counterions side by side in the same assay system to see whether the counterion, not the peptide sequence, changes the result. Sikora and colleagues compared antimicrobial peptides as TFA salts against the same sequences exchanged to other counterions, and reported differences in antistaphylococcal activity and cytotoxicity toward mammalian cells depending on which counterion was present, even with an identical peptide chain (Sikora et al., 2018). Greber and colleagues reported a related finding, that counterion type was a determinant of antimicrobial activity for short lipopeptides independent of net charge (Greber et al., 2017). A cytotoxicity or proliferation readout obtained with a TFA-salt peptide may not be solely attributable to the peptide's own mechanism, since residual TFA carried into the well can contribute to the signal, one documented reason some laboratories specify acetate or another exchanged salt for cell culture work.
How is a peptide exchanged from TFA to acetate or hydrochloride?
Salt exchange is a dedicated step performed after the peptide has already been purified, not a routine part of synthesis. Two approaches are common in the literature: passing the dissolved peptide over an ion-exchange resin that swaps the bound TFA anion for acetate or chloride, or repeated lyophilization from a dilute acetic acid or hydrochloric acid solution, which gradually displaces TFA with each freeze-dry cycle. Roux and colleagues evaluated several of these approaches and reported that efficiency varied by method and by sequence, so no single approach reliably removes all residual TFA (Roux et al., 2008). Counterion content after exchange is confirmed by a dedicated analytical method, such as ion chromatography or capillary electrophoresis, rather than inferred from HPLC purity (Mrozik et al., 2012).
How does the salt form appear on a certificate of analysis?
Where a COA lists salt form at all, it typically appears as a short line, such as "salt form: TFA" or "salt form: acetate," sometimes paired with a counterion-content percentage reported separately from purity and net peptide content. Not every COA includes this line, and its absence does not mean the peptide was exchanged, since TFA is the default outcome of standard purification and may simply go unlisted. General guidance on reading the rest of a COA is covered in how to read a peptide COA.
What does the BPC-157 arginate and acetate example illustrate?
BPC-157 is one of the peptides where salt form variation across suppliers is documented in practice. Some material is supplied as an acetate salt, the typical outcome of exchange from the default TFA form, while other lots are supplied as an arginate salt, which some suppliers frame as offering different powder handling or stability than acetate. The broader pharmaceutical salt-form literature supports the general principle behind this comparison: counterion and salt form choice measurably changes the physicochemical behavior of a peptide formulation, including stability, even when the sequence is unchanged (Moore et al., 2025). For background on BPC-157's structure, see what is BPC-157; lot-specific salt form details are listed on our BPC-157 lot page. A researcher comparing arginate and acetate lots should record salt form as its own specification line, separate from purity.
Frequently asked questions
Is a peptide's HPLC purity percentage the same as its counterion content?
No. HPLC purity describes how much of the chromatographic peak area corresponds to the intended peptide. Counterion content separately measures how much of the total solid weight is the bound salt ion, such as trifluoroacetate or acetate, rather than peptide.
Does a TFA salt mean a peptide is lower quality?
No. TFA is the default counterion produced by standard reverse-phase HPLC purification and is not an indicator of poor synthesis. It is a distinct specification, not a purity defect.
Why would a laboratory request an exchanged salt form instead of the default?
Some published cell culture comparisons report that counterion identity, not just peptide sequence, can change cytotoxicity and activity readouts in a given assay. Laboratories running cell-based work sometimes specify acetate or another exchanged salt to reduce this variable.
Can counterion content be measured directly rather than estimated?
Yes. Ion chromatography, capillary isotachophoresis, and capillary electrophoresis have been used in the literature to quantify counterion content in synthetic peptides directly, separate from HPLC-based purity testing.
Is BPC-157 only available as an acetate salt?
No. Vendor material documents BPC-157 supplied as acetate, arginate, and unexchanged TFA salt forms, and the salt form is generally listed as its own line on a lot-specific COA.
Does exchanging the salt form change the peptide's sequence or molecular structure?
No. Salt exchange changes only the counterion bound to the peptide's charged groups. The amino acid sequence and backbone are unaffected, only the identity and mass of the associated anion changes.
References
- Sikora K, Jaśkiewicz M, Neubauer D, et al. Counter-ion effect on antistaphylococcal activity and cytotoxicity of selected antimicrobial peptides. Amino Acids. 2018;50(5):609-619. PubMed 29307075.
- Roux S, Zékri E, Rousseau B, Paternostre M, Cintrat JC, Fay N. Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches. J Pept Sci. 2008;14(3):354-359. PubMed 18035848.
- Mrozik W, Markowska A, Guzik L, Kraska B, Kamysz W. Determination of counter-ions in synthetic peptides by ion chromatography, capillary isotachophoresis and capillary electrophoresis. J Pept Sci. 2012;18(3):192-198. PubMed 22252914.
- Greber KE, Dawgul M, Kamysz W, Sawicki W. Cationic net charge and counter ion type as antimicrobial activity determinant factors of short lipopeptides. Front Microbiol. 2017;8:123. PubMed 28203232.
- Moore JV, Cross ER, An Y, et al. Impact of counterion and salt form on the properties of long-acting injectable peptide hydrogels for drug delivery. Faraday Discuss. 2025;260:215-234. PubMed 40365687.
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.
